| ID | 115290 |
| Author |
Bando, Hiroshi
Tokushima University|Japan Low Carbohydrate Diet Promotion Association
KAKEN Search Researchers
|
| Keywords | Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) study
Canagliflozin cardioVascular Assessment Study (CANVAS)
Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study
The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study
sodium–glucose cotransporter 2 (SGLT2) inhibitors
|
| Content Type |
Journal Article
|
| Description | Patients with diabetes and heart failure have been increasing due to Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) study. β-blockers showed significantly suppressed cardiovascular events in the strict glycemic control group. Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) seem to be beneficial for diabetes and heart failure. Clinical efficacy of β-blockers would be suggested from three studies including Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) trial, Canagliflozin cardioVascular Assessment Study (CANVAS) and Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study. Further discussion will be expected with research in detail.
|
| Journal Title |
Endocrinology & Metabolism International Journal
|
| ISSN | 24730815
|
| Publisher | MedCrave Publishing
|
| Volume | 8
|
| Issue | 4
|
| Start Page | 97
|
| End Page | 99
|
| Published Date | 2020-08-31
|
| Rights | ©2020 Bando. This is an open access article distributed under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and build upon your work non-commercially.
|
| DOI (Published Version) | |
| URL ( Publisher's Version ) | |
| FullText File | |
| language |
eng
|
| TextVersion |
Publisher
|
| departments |
Medical Sciences
|
